Search

Your search keyword '"Feinberg, Mark W"' showing total 341 results
Start Over Author "Feinberg, Mark W" Language english
341 results on '"Feinberg, Mark W"'

16. Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease.

Author

Fowler, Xavier, Mehta, Kunal, Eid, Mark, Gladders, Barbara, Kearing, Stephen, Moore, Kayla O, Creager, Mark A, Austin, Andrea M, Feinberg, Mark W, Bonaca, Marc P, Greenland, Philip, McDermott, Mary M, and Goodney, Philip P

Subjects
PERIPHERAL vascular diseases, CONGESTIVE heart failure, FIBRINOLYTIC agents, MORTALITY risk factors, DEATH rate
Abstract

Introduction: Peripheral artery disease (PAD) is a well-described risk factor for mortality, but few studies have examined secular trends in mortality over time for patients with PAD. We characterized trends in mortality in patients with PAD in recent years among Medicare patients. Methods: We used Medicare claims to identify patients with a new diagnosis code for PAD between January 1, 2006 and December 31, 2018 using International Classification of Diseases (ICD) diagnosis codes. The primary outcome of interest was the 1-year all-cause age-adjusted mortality rate. Our secondary outcome was the 5-year all-cause mortality rate. Multivariable regression was used to identify factors which predict mortality at 1 year. Results: We identified 4,373,644 patients with a new diagnosis code for PAD during the study period. Between 2006 and 2018, 1-year all-cause age-adjusted mortality declined from 12.6% to 9.9% (p < 0.001). One-year crude all-cause mortality also declined from 14.6% to 9.5% (p < 0.001). Similar results were observed for 5-year age-adjusted mortality rates (40.9% to 35.2%, p < 0.001). Factors associated with increased risk of death at 1 year included age ⩾ 85 years (hazard ratio [HR] 3.030; 95% CI 3.008–3.053) and congestive heart failure (HR 1.86; 95% CI 1.85–1.88). Patients who were regularly dispensed statins, ace-inhibitors, beta-blockers, antithrombotic agents, and anticoagulants all had lower mortality (range OR 0.36; CI 0.35–0.37 for statins to OR 0.60; CI 0.59–0.61 for anticoagulants; all p < 0.001). Conclusion: Among US Medicare patients diagnosed with PAD between 2006 and 2019, 1-year age-adjusted mortality declined by 2.7%. This decline in mortality among patients with PAD occurred in the context of a younger mean age of diagnosis of PAD and improved cardiovascular prevention therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy.

Author

Moura, Filipe A., Bellavia, Andrea, Berg, David D., Melloni, Giorgio E. M., Feinberg, Mark W., Leiter, Lawrence A., Bohula, Erin A., Morrow, David A., Scirica, Benjamin A., Wiviott, Stephen D., and Sabatine, Marc S.

Subjects
TYPE 2 diabetes, INDIVIDUALIZED medicine, ANTIOBESITY agents, BODY mass index, WEIGHT loss
Abstract

Aims: To develop a clinical risk model to identify individuals at higher risk of developing new‐onset diabetes and who might benefit more from weight loss pharmacotherapy. Materials and Methods: A total of 21 143 patients without type 2 diabetes at baseline from two TIMI clinical trials of stable cardiovascular patients were divided into a derivation (~2/3) and validation (~1/3) cohort. The primary outcome was new‐onset diabetes. Twenty‐seven candidate risk variables were considered, and variable selection was performed using multivariable Cox regression. The final model was evaluated for discrimination and calibration, and for its ability to identify patients who experienced a larger benefit from the weight loss medication lorcaserin in terms of risk of new‐onset diabetes. Results: During a median (interquartile range) follow‐up of 2.3 (1.8–2.7) years, new‐onset diabetes occurred in 1013 patients (7.7%). The final model included five independent predictors (glycated haemoglobin, fasting glucose, age, body mass index, and triglycerides/high‐density lipoprotein). The clinical risk model showed good discrimination (Harrell's C‐indices 0.802, 95% confidence interval [CI] 0.788–0.817 and 0.807, 95% CI 0.788–0.826) in the derivation and validation cohorts. The calibration plot demonstrated adequate calibration (2.5‐year area under the curve was 81.2 [79.1–83.5]). While hazard ratios for new‐onset diabetes with a weight‐loss therapy were comparable across risk groups (annual risks of <1%, 1%–5%, and >5%), there was a sixfold gradient in absolute risk reduction from lowest to highest risk group (p = 0.027). Conclusions: The developed clinical risk model effectively predicts new‐onset diabetes, with potential implications for personalized patient care and therapeutic decision making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Abstract 10465: Abnormal Post Exercise Skeletal Muscle Microvascular Response and Metabolism Correlate With Patient Reported Outcomes in Patients With Intermittent Claudication From Peripheral Artery Disease

Author

Divakaran, Sanjay, Harms, Hans, Robertson, Matthew, Merugumala, Sai, Park, Mi-Ae, Kijewski, Marie, Martell, Laurel, Morgan, Victoria, Barrett, Leanne, Perillo, Anna, Bibbo, Courtney, Yang, David, Jarolim, Petr, Feinberg, Mark W, Lin, Alexander, Bonaca, Marc P, and DI CARLI, MARCELO

Published
2022
Full Text
View/download PDF

28. Injectable Self‐Oxygenating Cardio‐Protective and Tissue Adhesive Silk‐Based Hydrogel for Alleviating Ischemia After Mi Injury.

Author

Hassan, Shabir, Rezaei, Zahra, Luna, Eder, Yilmaz‐Aykut, Dilara, Lee, Myung Chul, Perea, Ana Marie, Jamaiyar, Anurag, Bassous, Nicole, Hirano, Minoru, Tourk, Fatima Mumtaza, Choi, Cholong, Becker, Malin, Yazdi, Iman, Fan, Kai, Avila‐Ramirez, Alan Eduardo, Ge, David, Abdi, Reza, Fisch, Sudeshna, Leijten, Jeroen, and Feinberg, Mark W.

Published
2024
Full Text
View/download PDF

33. American Heart Association Vascular Disease Strategically Focused Research Network

Author

Barnett, Joey V., Beckman, Joshua A., Bonaca, Marc P., Carnethon, Mercedes R., Cassis, Lisa A., Creager, Mark A., Daugherty, Alan, Feinberg, Mark W., Freiberg, Matthew S., Goodney, Philip P., Greenland, Philip, Leeuwenburgh, Christiaan, LeMaire, Scott A., McDermott, Mary M., Sabatine, Marc S., Shen, Ying H., Wasserman, David H., Webb, Nancy R., and Wells, Quinn S.

Published
2020
Full Text
View/download PDF

42. MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells

Author

Icli, Basak, Wu, Winona, Ozdemir, Denizhan, Li, Hao, Cheng, Henry S., Haemmig, Stefan, Liu, Xin, Giatsidis, Giorgio, Avci, Seyma Nazli, Lee, Nathan, Guimaraes, Raphael Boesch, Manica, Andre, Marchini, Julio F., Rynning, Stein Erik, Risnes, Ivar, Hollan, Ivana, Croce, Kevin, Yang, Xianbin, Orgill, Dennis P., and Feinberg, Mark W.

Published
2019
Full Text
View/download PDF

43. The Non-Coding RNA Journal Club: Highlights on Recent Papers—13.

Author

Shiu, Patrick K. T., DiStefano, Johanna K., Alahari, Suresh K., Enguita, Francisco J., Feinberg, Mark W., Sideris, Nikolaos, Bayraktar, Salih, Castellano, Leandro, Buitrago, Diana Luna, Caporali, Andrea, Mannucci, Alessandro, and Goel, Ajay

Subjects
NON-coding RNA, SMALL interfering RNA, LINCRNA, GENETIC variation, CORONARY artery disease
Abstract

This document summarizes the thirteenth Journal Club from the journal Non-Coding RNA, which includes five highlighted papers. The first paper focuses on the regulation of trans-species microRNAs in a parasitic plant, while the second paper explores the role of specific RNA domains in maintaining membraneless organelles within the nucleus. The third paper discusses the identification of BRCA1/2 mutation carriers using circulating microRNAs, and the fourth paper examines the role of DICER nuclease in resolving R-loops. The final paper investigates the impact of heterogeneity in alternatively expressed lncRNA on the penetrance of coronary artery disease. The document also provides a brief summary of each paper's findings, including the role of genetic variations in increasing the risk of coronary artery disease, the role of a long non-coding RNA in cardiac hypertrophy, the correlation between certain microRNAs and aging, and the potential use of small interfering RNAs as a treatment for chronic hepatitis B. [Extracted from the article]

Published
2023
Full Text
View/download PDF

44. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.

Author

Moura, Filipe A., Berg, David D., Bellavia, Andrea, Dwyer, Jamie P., Mosenzon, Ofri, Scirica, Benjamin M., Wiviott, Stephen D., Bhatt, Deepak L., Raz, Itamar, Feinberg, Mark W., Braunwald, Eugene, Morrow, David A., and Sabatine, Marc S.

Subjects
DISEASE risk factors, DAPAGLIFLOZIN, CANAGLIFLOZIN, TYPE 2 diabetes, DISEASE progression, CHRONIC kidney failure, SYSTOLIC blood pressure
Abstract

OBJECTIVE: To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium–glucose cotransporter 2 (SGLT2) inhibition. RESEARCH DESIGN AND METHODS: A total of 41,204 patients with T2D from four Thrombolysis In Myocardial Infarction (TIMI) clinical trials were divided into derivation (70%) and validation cohorts (30%). Candidate predictors of kidney disease progression (composite of sustained ≥40% decline in estimated glomerular filtration rate [eGFR], end-stage kidney disease, or kidney death) were selected with multivariable Cox regression. Efficacy of dapagliflozin was assessed by risk categories (low: <0.5%; intermediate: 0.5 to <2%; high: ≥2%) in Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58. RESULTS: There were 695 events over a median follow-up of 2.4 years. The final model comprised eight independent predictors of kidney disease progression: atherosclerotic cardiovascular disease, heart failure, systolic blood pressure, T2D duration, glycated hemoglobin, eGFR, urine albumin-to-creatinine ratio, and hemoglobin. The c-indices were 0.798 (95% CI, 0.774–0.821) and 0.798 (95% CI, 0.765–0.831) in the derivation and validation cohort, respectively. The calibration plot slope (deciles of predicted vs. observed risk) was 0.98 (95% CI, 0.93–1.04) in the validation cohort. Whereas relative risk reductions with dapagliflozin did not differ across risk categories, there was greater absolute risk reduction in patients with higher baseline risk, with a 3.5% absolute risk reduction in kidney disease progression at 4 years in the highest risk group (≥1%/year). Results were similar with the 2022 Chronic Kidney Disease Prognosis Consortium risk prediction model. CONCLUSIONS: Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Can removal of zombie cells revitalize the aging cardiovascular system?

Author

Saravi, Seyed Soheil Saeedi and Feinberg, Mark W

Subjects
CARDIOVASCULAR system, CELLULAR aging, CARDIOVASCULAR diseases, OLDER people, PRESBYCUSIS, PREMATURE aging (Medicine), DNA repair
Abstract

The article discusses the role of senescent cells, also known as "zombie cells," in the aging process and their impact on the cardiovascular system. These cells accumulate in the body as we age and secrete harmful substances that can damage neighboring cells, leading to a decline in tissue function and age-related diseases. The article explores the potential of senolytics, which eliminate senescent cells, and senomorphics, which suppress the inflammatory secretome associated with senescence, as therapeutic approaches to rejuvenate the cardiovascular system. The challenges in developing these treatments include identifying senescence biomarkers, minimizing off-target effects, and determining optimal timing and treatment duration. The article concludes that the removal of senescent cells shows promise in mitigating cardiovascular risk in the elderly and calls for further research and clinical trials to advance the field. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results